Saram ConsultingGxP & AI Consulting for Life Sciences. Custom AI integrations, Part 11 compliance validation, and equity-based engineering partnerships for biotech.Explore Services at saram.io →
← Back to Home

Pierre Fabre

Private
#Oncology#Dermatology#Rare Diseases#Consumer Health

Pierre Fabre is a French pharmaceutical and dermo-cosmetics group whose portfolio spans oncology, dermatology, rare diseases and consumer health, and whose cell therapy tabelecleucel is under FDA review for Epstein-Barr virus-positive post-transplant lymphoproliferative disease.

Company Info

Sector:Pharmaceuticals
Headquarters:Castres, France
Founded:1962
Website:www.pierre-fabre.com/en

Upcoming Milestones & Key Dates

2026-2027
PDUFA / Review

FDA review of resubmitted tabelecleucel BLA

Clinical Development Pipeline

tabelecleucel

Target: EBV-infected B cells
Epstein-Barr virus-positive post-transplant lymphoproliferative disease
Preclinical
Phase 1
Phase 2
Phase 3
Approved

Oncology pipeline

Target: Multiple
Solid tumors and hematologic cancers
Preclinical
Phase 1
Phase 2
Phase 3
Approved

Recent News

Leadership Team

Careers & Job Openings

Responsable de secteur Avène - Secteur Nouvelle-Aquitaine et Occitanie - CDD - H/F

General
5 Locations
Apply Now →

AI SOLUTIONS ARCHITECT & ENGINEER - M/F- CDI

General
Tarn (81)
Apply Now →

Data Engineering Lead- R&D pharma- M/F - CDI

General
Haute Garonne (31)
Apply Now →